BioCryst Pharmaceuticals Inc 2024年度报告

Form10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year endedDecember31, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number000-23186 BIOCRYST PHARMACEUTICALS, INC.(Exact name of registrant as specified in its charter) 62-1413174 (I.R.S. EmployerIdentification No.) (State or other jurisdictionof incorporation or organization) 4505 Emperor Blvd., Suite 200,Durham,North Carolina27703(Address of principal executive offices) (919)859-1302(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act Name of each exchange on whichregistered Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None. Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YesoNox Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.YesxNoo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerxAccelerated fileroNon-accelerated fileroSmaller reporting companyoEmerging growth companyo If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.x If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.o Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesoNox The registrant estimates that the aggregate market value of the Common Stock on June30, 2024 (based upon the closing price shownon the Nasdaq Global Select Market on June30, 2024) held by non-affiliates was $1,264,650,517. The number of shares of Common Stock, par value $0.01, of the registrant outstanding as of February20, 2025 was208,960,020shares. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement to be filed in connection with the solicitation of proxies for its 2025 annualmeeting of stockholders are incorporated by reference into Items 10, 11, 12, 13, and 14 under Part III hereof. TABLE OF CONTENTS Cautionary Note Regarding Forward-Looking Statements1Risk Factor Summary2PART IITEM 1. BUSINESS5ITEM 1A. RISK FACTORS28ITEM 1B. UNRESOLVED STAFF COMMENTS58ITEM 1C. CYBERSECURITY58ITEM 2. PROPERTIES60ITEM 3. LEGAL PROCEEDINGS60ITEM 4. MINE SAFETY DISCLOSURES60PART IIITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, ANDISSUER PURCHASES OF EQUITY SECURITIES61ITEM 6. RESERVED62ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS62ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK75ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA77ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIALDISCLOSURE116ITEM 9A. CONTROLS AND PROCEDURES116ITEM 9B. OTHER INFORMATION117ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS117PART IIIITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE118ITEM 11. EXECUTIVE COMPENSATION118ITEM 12. SECURITY OWNERSHIP OF CERTAIN